Aeterna Zentaris Announces Effective Date of Share Consolidation
18 juil. 2022 17h06 HE
|
Aeterna Zentaris Inc
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
15 juil. 2022 16h15 HE
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
06 juil. 2022 16h05 HE
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
21 juin 2022 16h01 HE
|
Aeterna Zentaris Inc
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a...
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program
13 juin 2022 08h00 HE
|
Aeterna Zentaris Inc
– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD") – Positive results presented at the 13th...
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference
09 juin 2022 08h00 HE
|
Aeterna Zentaris Inc
Live video webcast on Wednesday, June 15th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency
25 mai 2022 08h00 HE
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, May 25, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
18 mai 2022 08h00 HE
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation
16 mai 2022 08h00 HE
|
Aeterna Zentaris Inc
TORONTO, ON, May 16, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
12 mai 2022 08h05 HE
|
Aeterna Zentaris Inc
– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity Modifying (“AIM”) Biologicals as a potential...